316 related articles for article (PubMed ID: 24121496)
1. Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications.
Grosse L; Pâquet S; Caron P; Fazli L; Rennie PS; Bélanger A; Barbier O
Cancer Res; 2013 Dec; 73(23):6963-71. PubMed ID: 24121496
[TBL] [Abstract][Full Text] [Related]
2. Multiple roles for UDP-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes in androgen metabolism and prostate cancer evolution.
Gauthier-Landry L; Bélanger A; Barbier O
J Steroid Biochem Mol Biol; 2015 Jan; 145():187-92. PubMed ID: 24861263
[TBL] [Abstract][Full Text] [Related]
3. Calcitrol (1alpha,25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells.
Kaeding J; Bélanger J; Caron P; Verreault M; Bélanger A; Barbier O
Mol Cancer Ther; 2008 Feb; 7(2):380-90. PubMed ID: 18281521
[TBL] [Abstract][Full Text] [Related]
4. Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells.
Kaeding J; Bouchaert E; Bélanger J; Caron P; Chouinard S; Verreault M; Larouche O; Pelletier G; Staels B; Bélanger A; Barbier O
Biochem J; 2008 Mar; 410(2):245-53. PubMed ID: 17988216
[TBL] [Abstract][Full Text] [Related]
5. Characterization and regulation of UDP-glucuronosyltransferases in steroid target tissues.
Bélanger A; Hum DW; Beaulieu M; Lévesque E; Guillemette C; Tchernof A; Bélanger G; Turgeon D; Dubois S
J Steroid Biochem Mol Biol; 1998 Apr; 65(1-6):301-10. PubMed ID: 9699884
[TBL] [Abstract][Full Text] [Related]
6. Loss of exogenous androgen dependence by prostate tumor cells is associated with elevated glucuronidation potential.
Zimmer BM; Howell ME; Wei Q; Ma L; Romsdahl T; Loughman EG; Markham JE; Seravalli J; Barycki JJ; Simpson MA
Horm Cancer; 2016 Aug; 7(4):260-71. PubMed ID: 27307252
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression.
Pâquet S; Fazli L; Grosse L; Verreault M; Têtu B; Rennie PS; Bélanger A; Barbier O
J Clin Endocrinol Metab; 2012 Mar; 97(3):E428-32. PubMed ID: 22170718
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic regulation of steroid inactivating UDP-glucuronosyltransferases by microRNAs in prostate cancer.
Margaillan G; Lévesque É; Guillemette C
J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):85-93. PubMed ID: 26385605
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of androgens by UDP-glucuronosyltransferases in the human prostate.
Barbier O; Bélanger A
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):259-70. PubMed ID: 18471784
[TBL] [Abstract][Full Text] [Related]
10. Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism.
Braadland PR; Grytli HH; Ramberg H; Katz B; Kellman R; Gauthier-Landry L; Fazli L; Krobert KA; Wang W; Levy FO; Bjartell A; Berge V; Rennie PS; Mellgren G; Mælandsmo GM; Svindland A; Barbier O; Taskén KA
Oncotarget; 2016 Jan; 7(2):1878-94. PubMed ID: 26646591
[TBL] [Abstract][Full Text] [Related]
11. UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells.
Chouinard S; Barbier O; Bélanger A
J Biol Chem; 2007 Nov; 282(46):33466-33474. PubMed ID: 17848572
[TBL] [Abstract][Full Text] [Related]
12. Androgen-independent growth in LNCaP cell lines and steroid uridine diphosphate-glucuronosyltransferase expression.
Kanaya J; Takashima M; Koh E; Namiki M
Asian J Androl; 2003 Mar; 5(1):9-13. PubMed ID: 12646996
[TBL] [Abstract][Full Text] [Related]
13. Regulation of Human UGT2B15 and UGT2B17 by miR-376c in Prostate Cancer Cell Lines.
Wijayakumara DD; Hu DG; Meech R; McKinnon RA; Mackenzie PI
J Pharmacol Exp Ther; 2015 Sep; 354(3):417-25. PubMed ID: 26163549
[TBL] [Abstract][Full Text] [Related]
14. Forkhead box protein A1 regulates UDP-glucuronosyltransferase 2B15 gene transcription in LNCaP prostate cancer cells.
Hu DG; Mackenzie PI
Drug Metab Dispos; 2010 Dec; 38(12):2105-9. PubMed ID: 20736324
[TBL] [Abstract][Full Text] [Related]
15. Genetic variations in UGT2B28, UGT2B17, UGT2B15 genes and the risk of prostate cancer: A case-control study.
Habibi M; Mirfakhraie R; Khani M; Rakhshan A; Azargashb E; Pouresmaeili F
Gene; 2017 Nov; 634():47-52. PubMed ID: 28882566
[TBL] [Abstract][Full Text] [Related]
16. Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyltransferase expression and activity in the LNCaP cell line.
Lévesque E; Beaulieu M; Guillemette C; Hum DW; Bélanger A
Endocrinology; 1998 May; 139(5):2375-81. PubMed ID: 9564848
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes.
Bao BY; Chuang BF; Wang Q; Sartor O; Balk SP; Brown M; Kantoff PW; Lee GS
Prostate; 2008 Jun; 68(8):839-48. PubMed ID: 18302198
[TBL] [Abstract][Full Text] [Related]
18. Estrogen regulation of the glucuronidation enzyme UGT2B15 in estrogen receptor-positive breast cancer cells.
Harrington WR; Sengupta S; Katzenellenbogen BS
Endocrinology; 2006 Aug; 147(8):3843-50. PubMed ID: 16690804
[TBL] [Abstract][Full Text] [Related]
19. A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.
Cai Y; Lee YF; Li G; Liu S; Bao BY; Huang J; Hsu CL; Chang C
Int J Cancer; 2008 Jul; 123(1):195-201. PubMed ID: 18386814
[TBL] [Abstract][Full Text] [Related]
20. Exemestane and Its Active Metabolite 17-Hydroexemestane Induce UDP-Glucuronosyltransferase (UGT) 2B17 Expression in Breast Cancer Cells.
Chanawong A; Mackenzie PI; McKinnon RA; Hu DG; Meech R
J Pharmacol Exp Ther; 2017 Jun; 361(3):482-491. PubMed ID: 28404691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
